CDEK by Data4ThePeople
IndicationsMechanismsTrialsFDA ApprovalsAbout
Sign in Sign up
IndicationsMechanismsTrialsFDA ApprovalsAbout
← All indications

Insulinoma

A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.

Drugs by status

Approved for this indication (1)

  • diazoxide

Phase 2 trials (12)

  • sorafenib
  • dovitinib
  • regorafenib
  • pasireotide
  • temozolomide
  • bevacizumab
  • everolimus
  • capecitabine
  • gefitinib
  • romidepsin
  • sodium chloride
  • 177lu-dotatoc

Phase 1 trials (8)

  • 68ga-nota-exendin-4
  • fluorodopa
  • paclitaxel
  • trastuzumab
  • carboplatin
  • interleukin-12
  • vatalanib
  • [68ga]ga-hbed-cc-exendin-4

Other trials (1)

  • 18f-6-l-fluorodihydroxyphenylalanine

Organizations

Organization Involved with Phase 2 Indications (12)

  • Novartis
  • National Cancer Institute (NCI)
  • Academic and Community Cancer Research United
  • Eastern Cooperative Oncology Group
  • ECOG-ACRIN Cancer Research Group
  • Emory University
  • Ohio State University
  • Stanford University
  • University of Southern California
  • Mayo Clinic
  • University of Texas at Houston
  • Yeshiva University

Organization Involved with Phase 1 Indications (5)

  • National Institutes of Health (NIH)
  • Nanjing Medical University
  • Vanderbilt University
  • Tsinghua University
  • Cook Children's Medical Center

Organization Involved with Other Experimental Indications (2)

  • British Columbia Cancer Agency
  • University of Pennsylvania

CDEK

The Clinical Drug Experience Knowledgebase — tracking drugs, sponsoring organizations, and clinical trials from first-in-human testing through approval.

Browse

  • Drugs
  • Organizations
  • Trials

About

  • About CDEK
  • Glossary

Built and maintained by Data4ThePeople.

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED "AS IS", WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.